Effects of verapamil on indexes of heart rate variability after acute myocardial infarction. 1998

E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
Department of Cardiology, General Hospital of the University of Murcia, Spain.

In patients with previous myocardial infarction (MI), depressed heart rate variability (HRV) may reflect a reduction in vagal activity and lead to cardiac electrical instability. Interventions designed to increase HRV may be of clinical interest. Data on the effects of calcium antagonists on HRV in post-MI patients are very limited. The aim of our study was to assess the effects of verapamil on HRV and on the sympathovagal balance after MI. Fifty consecutive patients with a first MI, stable sinus rhythm, and left ventricular ejection fraction >0.40 were studied. Each patient underwent two 24-hour Holter recordings, 1 at baseline and another after 4 days of treatment with verapamil retard (180 mg 2 times daily). Time and frequency domain parameters of HRV were analyzed. All time domain measurements increased significantly after verapamil: the standard deviation of all NN intervals (SDNN) from 87.1 +/- 31.4 to 98.1 +/- 30.3 ms (p <0.05) and the log-transformed percentage of pairs of adjacent NN intervals that differ >50 ms (pNN50) from 0.57 +/- 0.42 to 0.76 +/- 0.45 (p <0.01). The standard deviation of the averages of RR interevals (SDANN) (75.9 +/- 30.1 vs 86.3 +/- 29.4 ms, p <0.05), root-mean-square of successive differences between RR intervals (rMSSD) (23.0 +/- 11.7 and 28.1 +/- 13.1 ms, p <0.01), and the triangular HRV index (28.3 +/- 9.6 vs 23.4 +/- 8.6, p <0.001) also increased. A significant inverse correlation was found between improvement in HRV indexes induced by verapamil and baseline values. Spectral analysis showed a significant increase in high-frequency power of 58.5% without changes in low and very low components. With normalized units, significant reductions in low-frequency power and low- to high-frequency ratio were observed. Diabetic patients did not show any significant changes in HRV on administration of verapamil. These findings indicate that verapamil, administered during the subacute phase of MI, improves both global and short-period indexes of HRV and induces a shift in the sympathetic-parasympathetic interaction toward vagal predominance. This effect may contribute to an explanation of the beneficial effects of verapamil that have been reported in post-MI patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
July 1998, Cardiovascular drugs and therapy,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
March 1997, The American journal of cardiology,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
March 1993, American heart journal,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
February 1999, International journal of cardiology,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
July 2004, Medical science monitor : international medical journal of experimental and clinical research,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
January 2012, Frontiers in physiology,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
August 1994, The American journal of cardiology,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
January 2009, Cardiology,
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
January 1996, Clinical science (London, England : 1979),
E Pinar, and A García-Alberola, and C Llamas, and T Vicente, and J López-Candel, and J L Rojo, and R Fernández, and M Valdés
April 2011, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc,
Copied contents to your clipboard!